logo-loader
viewSeelos Therapeutics

Seelos Therapeutics looks to raise $4.3M in latest offering

Under the terms, 6,666,667 shares of Seelos stock will be sold at a price of $0.75 per share

Seelos Therapeutics -
Dr. Raj Mehra, CEO, founder and chairman of the Seelos board, intends to purchase shares in the offering

Seelos Therapeutics (NASDAQ:SEEL), is set to raise net proceeds of $4.3 million to advance the drugs in its pipeline, thanks to its latest public offering. 

Under the terms of the offering, 6,666,667 shares of Seelos stock will be sold at a price of $0.75 per share. Underwriters have also been awarded a 45-day option to purchase up to 999,999 additional shares to cover over-allotments. 

READ: Seelos Therapeutics has catalysts for its ketamine depression drug, multiple shots on goal with a strong pipeline

Dr. Raj Mehra, CEO, founder and chairman of the Seelos board, intends to purchase shares in the offering, which is set to close on or around February 13, at the set price. Benchmark Company is acting as the sole book-runner for the offering.

Seelos is a New York clinical-stage biopharmaceutical company focused on central nervous system, neurological and psychiatric disorders.

Quick facts: Seelos Therapeutics

Price: 1.03 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $46.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read